News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Large-scale global serologic surveillance with real-time monitoring of the immune status of human populations and detection of viral outbreaks could be enabled by new technology from Picodya.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
WuXi AppTec has commissioned two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.